Sumitomo Pharma America receives USFDA approval of vibegron for benign prostatic hyperplasia
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
The investment will empower RDHL to develop a virtual diagnostic and care platform, expanding access to healthcare for underserved communities
FDC Ltd has received final approval from USFDA for the company's Abbreviated New Drug Application (ANDA) for Cefixime 400 mg Tablets
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management
In the US, the compassionate use approvals are provided by FDA in the form of individual patient-specific expanded-access IND
Merck has also decided to end the favezelimab clinical development program
Subscribe To Our Newsletter & Stay Updated